Myocardial ischemia/reperfusion injury (MI/RI) remains a major therapeutic challenge in acute myocardial infarction due to ...

The elderly account for the majority of medical spending in many countries, raising concerns about potentially unnecessary spending, especially during the final months of life. Using a well-defined ...

Hypereosinophilic syndrome (HES) is a heterogeneous disorder characterised by persistent, abnormal eosinophil elevation in ...

Background Guidelines strongly recommend reperfusion therapy, including thrombolysis and percutaneous coronary intervention, ...

Researchers from Mass General Brigham have unveiled the results of a large clinical trial that found that adding the drug ...

DelveInsight's, “Myocardial Infarction Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 40+ pipeline drugs in Myocardial Infarction pipeline landscape. It covers ...

While there are therapies to aid in overall heart health, there are very few preventative therapies for heart failure after a significant heart attack, a serious condition that has a very significant ...

Adding the PCSK9 inhibitor evolocumab to standard lipid-lowering therapy significantly reduced first major cardiovascular ...

The authors collected resource utilization and cost of treatment data (in US dollars, excluding physicians' fees) from the cost accounting systems of two Canadian hospitals (n=215) and seven US ...

Pune, Maharashtra, India, September 17 2020 (Wiredrelease) Prudour Pvt. Ltd –:The latest research report published by Market.us on Geographical and Global Myocardial Infarction Treatment Market is a ...